These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2502310)

  • 1. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
    Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
    Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and functional analysis of human CD3+ and CD3- clones with "lymphokine-activated killer" (LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin-2.
    Mingari MC; Ferrini S; Pende D; Bottino C; Prigione I; Moretta A; Moretta L
    Int J Cancer; 1987 Oct; 40(4):495-8. PubMed ID: 3117711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
    Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
    Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of lymphokine-activated killer (LAK) populations at the clonal level: both NK and CD3+, CD4-, CD8- clones efficiently mediate tumor cell killing.
    Gerosa F; Tommasi M; Spiazzi AL; Azzolina LS; Carra G; Maffei A; Accolla RS; Tridente G
    Clin Immunol Immunopathol; 1988 Oct; 49(1):91-100. PubMed ID: 2970356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
    Ozdemir O; Ravindranath Y; Savaşan S
    J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic analyses of lymphokine-activated killer cells that release interferon gamma and tumor necrosis factor alpha.
    Chong AS; Ybarrondo B; Grimes WJ; Hersh EM; Scuderi P
    Cancer Immunol Immunother; 1990; 31(4):255-9. PubMed ID: 2143102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.
    Shau H; Gray JD; Golub SH
    Cancer Immunol Immunother; 1988; 27(3):255-60. PubMed ID: 2972366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
    J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
    Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
    Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules.
    Chong AS; Boussy IA; Graf LH; Scuderi P
    Cell Immunol; 1992 Oct; 144(1):69-79. PubMed ID: 1356634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
    Koberda J; Bergmann L; Mitrou PS; Hoelzer D
    J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells.
    Bensussan A; Lagabrielle JF; Castaigne S; Boisson N; Miclea JM; Benbunan M; Degos L
    Nouv Rev Fr Hematol (1978); 1989; 31(2):129-32. PubMed ID: 2528119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells.
    Moretta L; Pende D; Cozzani R; Merli A; Bagnasco M; Mingari MC
    Eur J Immunol; 1986 Dec; 16(12):1623-5. PubMed ID: 3102249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.